What's new with Wegovy: the latest UK developments explained

The 7.2mg pen: what the MHRA's April approval actually confirmed

Before April 2026, a 7.2mg weekly semaglutide dose was technically available, but only as three separate 2.4mg pens. The MHRA's announcement on 14 April 2026 approved a single dedicated 7.2mg pen: one injection, pre-set, with an auto-dosing mechanism, a covered needle, and a lock after use. That's a meaningful convenience change, not just a regulatory footnote.

Trial data attached to the higher dose reported around 20.7% average weight loss over 72 weeks, which narrows the gap with tirzepatide at its maintenance dose. The MHRA's official announcement confirms the 7.2mg pen is licensed for adults with a BMI of 30 or above, not for people below that threshold, and not for the cardiovascular indication. Starting dose remains 0.25mg; a prescriber titrates upward over several months. If you're reading about this dose and wondering whether it's right for you, that's exactly the kind of question our clinical team works through at consultation.

Worth noting: whether a specific pen format is available depends on supply at the time of your consultation, and if you're coming to Wegovy for the first time, our new customer page walks through what to expect at that first step. A prescriber can confirm what's accessible rather than you having to cross-reference stock lists.

The Wegovy tablet: what the June 2026 licensing actually means for people who dislike injections

The oral semaglutide tablet (branded Wegovy, co-formulated with an absorption enhancer called SNAC) received MHRA approval on 11 June 2026. The UK was the first country in Europe to license it for weight management, which is worth stating plainly because a lot of what circulates online conflates it with Rybelsus, the oral semaglutide tablet licensed for type 2 diabetes. They are different products with different dose schedules and different licensed uses. If you've been researching new semaglutide options, the Wegovy tablet is the one relevant to weight management.

The licensed dose ladder for the tablet is 1.5mg → 4mg → 9mg → 25mg, with at least a month at each step. It's taken first thing in the morning on an empty stomach, with a small amount of plain water, and you wait at least 30 minutes before food, coffee, or other oral medicines. No refrigeration required, the tablet stores at room temperature, which matters for people who travel frequently or share a small fridge.

Phase 3 trial data from the OASIS 4 study (307 adults, 64 weeks, versus placebo) showed roughly 13.6% average weight loss. Among participants who adhered fully to treatment throughout the trial, the figure rose to around 17%. The most common side effects were gastrointestinal (nausea, diarrhoea, vomiting) affecting 74% of the tablet group compared with 42% on placebo, though most were mild to moderate and settled over time. The NHS medicines page for semaglutide is a reliable starting point for understanding the broader side-effect picture.

There's no NHS route to the Wegovy tablet yet, NICE would need to complete an appraisal before it could be commissioned. Private prescription is the only current route. For a fuller picture of how the tablet fits alongside the injection, the Wegovy overview page covers both.

The MASH approval, and why it matters even if you're not treating liver disease

On 3 July 2026 the MHRA granted Wegovy a conditional approval to treat MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis in adults. MASH is a progressive form of fatty liver disease with very limited treatment options, so this is clinically significant in its own right.

For people using Wegovy for weight management, the practical significance is subtler: it reinforces that semaglutide's effects extend well beyond appetite. Weight loss itself reduces liver fat, and trials have tracked improvements in liver markers alongside weight changes. If you have a liver condition and are considering weight management treatment, that's a conversation to have openly with your prescriber, not something to self-navigate based on a headline.

The MHRA's announcement on 3 July 2026 covers the specifics. At nume, prescribers assess the full clinical picture, including conditions beyond the primary reason someone's seeking treatment.

Checking whether anything you've read is current

Wegovy's regulatory story has moved quickly. One habit that takes under a minute: when you see a claim about a new dose, approval or availability, check the date it was published. Anything written before January 2026 predates the 7.2mg dose approval; anything before June 2026 predates the tablet. The Wegovy news page tracks verified UK-specific updates as they happen.

For broader context on how semaglutide compares with other licensed options and what the evidence shows across products, the semaglutide overview is worth reading alongside this page. And if you want to understand pricing for private Wegovy treatment, the cost context page addresses the questions people actually ask about what they'll pay and what's included.

If the developments above have made you want to start a conversation about which route (injection or tablet, current or titrated dose) might suit your situation, speak to our prescribers. The consultation is free, and a clinician reviews your answers the same day.